Addendum
Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Addendum to Commission A22-81
Report documents
-
Addendum
Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Addendum to Commission A22-81
Dossier assessment
Indication:
Adults with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more HER2-targeted therapies
Result of dossier assessment:
After addendum now hint of considerable added benefit
Press releases
Advanced breast cancer: now considerable added benefit of trastuzumab deruxtecan
New results from an early initiated study show advantages in overall survival.
Additional information
Federal Joint Committee (G-BA)
2023-02-02 A G-BA decision was published.
Project details
- Project no.
- A22-127
- Commission
- Commission awarded on 06.12.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed